EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach

Rune Viig Overgaard iD, Oscar Birkhan iD, Naveen Rathor, Thomas Sparsø, Anders Strathe iD, Sean Wharton iD, Domenica Rubino

Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 5982-5991

DOI: 10.1111/dom.70769 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 23.04.2026. Verfasst von Rune Viig Overgaard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk A/S, Søborg, Denmark. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Obesity. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Semaglutide has previously been approved for weight management and cardiovascular disease as a subcutaneous formulation, and more recently also as an oral formulation. However, there is limited information across oral dose levels, and there are no studies for the 25 mg dose in people with obesity and type 2 diabetes (T2D). To fulfil health authority approval requirements, population pharmacokinetic and exposure–response analyses were used to extrapolate efficacy and safety data from subcutaneous to oral semaglutide. Materials and Methods Once‐daily oral semaglutide 25 mg was approved for obesity treatment based on historical semaglutide data and the OASIS programme. Two studies were simulated: a modelled/virtual Phase 2 trial to establish efficacy across different oral semaglutide dose levels, and a modelled/virtual Phase 3 trial to assess efficacy in a population with overweight/obesity and T2D.

Results

Most participants (82.2%) treated with oral semaglutide 25 mg in OASIS 4 achieved exposure levels within the same range as participants treated with once‐weekly subcutaneous semaglutide 2.4 mg in STEP 1. In the simulated studies, oral semaglutide 25 mg provided significantly greater weight reduction compared with placebo, for the trial product estimand and treatment policy estimand, respectively, in those with overweight/obesity and T2D (9.4% and 7.8%), and in those with overweight/obesity without T2D (16.3% and 14.7%).

Conclusions

Estimated exposure levels and efficacy observed with oral semaglutide 25 mg were similar to those obtained with subcutaneous semaglutide 2.4 mg, supporting application of oral semaglutide 25 mg to treat individuals with overweight/obesity, with/without T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsDiabetes Mellitus, Type 2Hypoglycemic AgentsObesitySemaglutideAdultFemaleHumansMaleMiddle AgedAdministration, OralDrug Administration ScheduleDrug DevelopmentInjections, SubcutaneousTreatment OutcomeWeight Loss

Stichwörter der Autor:innen

GLP‐1 analoguepharmacokineticssemaglutidetype 2 diabetesweight management

Substanzen

Anti-Obesity AgentsHypoglycemic AgentsSemaglutide

Autor:innen und Institutionen

  • Novo Nordisk A/S, Søborg, Denmark.
  • University of Toronto, York University, McMaster University, Wharton Weight Management Clinic, Burlington, Ontario, Canada.
  • Washington Center for Weight Management and Research, Arlington, Virginia, USA.

ORCID-Profile: Rune Viig Overgaard, Oscar Birkhan, Anders Strathe, Sean Wharton

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Overgaard, R. V., Birkhan, O., Rathor, N., Sparsø, T., Strathe, A., Wharton, S., & Rubino, D. (2026). Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach. Diabetes, Obesity and Metabolism, 28(7), 5982-5991. https://doi.org/10.1111/dom.70769

Vancouver

Overgaard RV, Birkhan O, Rathor N, Sparsø T, Strathe A, Wharton S, et al. Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach. Diabetes, Obesity and Metabolism. 2026;28(7):5982-5991. doi:10.1111/dom.70769

BibTeX
@article{Overgaard2026,
  author = {Overgaard, Rune Viig and Birkhan, Oscar and Rathor, Naveen and Sparsø, Thomas and Strathe, Anders and Wharton, Sean and Rubino, Domenica},
  title = {Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {7},
  pages = {5982--5991},
  doi = {10.1111/dom.70769}
}
Kostenlos starten →